DexCom (NASDAQ:DXCM – Get Free Report) and DENTSPLY SIRONA (NASDAQ:XRAY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Valuation and Earnings
This table compares DexCom and DENTSPLY SIRONA”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DexCom | $4.66 billion | 6.72 | $836.30 million | $2.53 | 32.82 |
| DENTSPLY SIRONA | $3.68 billion | 0.57 | -$598.00 million | ($2.75) | -3.80 |
Institutional and Insider Ownership
97.8% of DexCom shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for DexCom and DENTSPLY SIRONA, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DexCom | 1 | 2 | 21 | 2 | 2.92 |
| DENTSPLY SIRONA | 3 | 9 | 3 | 0 | 2.00 |
DexCom presently has a consensus target price of $88.71, indicating a potential upside of 6.84%. DENTSPLY SIRONA has a consensus target price of $13.54, indicating a potential upside of 29.43%. Given DENTSPLY SIRONA’s higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than DexCom.
Profitability
This table compares DexCom and DENTSPLY SIRONA’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DexCom | 20.12% | 35.94% | 14.75% |
| DENTSPLY SIRONA | -14.99% | 20.84% | 5.32% |
Risk & Volatility
DexCom has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Summary
DexCom beats DENTSPLY SIRONA on 13 of the 15 factors compared between the two stocks.
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform. It also provides endodontic products consisting of motorized endodontic handpieces, files, sealers, irrigation needles, and other tools that support root canal procedures; restorative products, including dental ceramics, crowns, and veneers; and preventative products, such as curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, and impression materials. In addition, the company offers SureSmile and Byte aligner solutions; VPro/HyperByte, a high-frequency vibration technology device; SureSmile Simulator, which creates a 3D visualization of a patient's outcome; and Byte Plus for treatment planning. Further, it provides dental implants, digital dentures, crown and bridge porcelain products, bone regenerative and restorative solutions, treatment planning software, and educational programs; dental prosthetics; urology catheters; and other health-related consumables. The company serves professional dental and consumable medical device markets through third-party distributors. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
